Chlorhexidine gluconate
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | DYNA-HEX 2 | — | 1989-12-27 – 2003-12-19 | fda.gov ↗ |
| Label expansion | US (FDA) | HIBICLENS | — | 1982-03-01 | fda.gov ↗ |
| Approved | US (FDA) | HIBICLENS | — | 1976-09-17 | fda.gov ↗ |
Trials 109 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03787082 | Dec 2022 → Dec 2023 | diastolic heart failure, pulmonary hypertension | Gladwin, Mark, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT03331263 | Jul → Aug 2017 | — | Medline Industries | Completed | No outcome recorded |
| Phase 1 | NCT02326467 | Feb 2016 → Sep 2018 | drug pseudoallergy, exanthem, infectious disease | Celeste Chandonnet | Completed | No outcome recorded |
| Phase 1 | NCT02001311 | Jan → Apr 2014 | dental caries, malposition of teeth with or without hypodontia/oligodontia | King Abdulaziz University | Unknown | No outcome recorded |
| Phase 1 | NCT02337192 | Jan → Jun 2014 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT01036412 | Dec 2009 → Aug 2012 | head and neck cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00130221 | Jun 2005 → Jun 2006 | Clostridium infectious disease, infectious disease with sepsis, nosocomial infection, pneumonia +1 | Cook County Health | Completed | No outcome recorded |
| Phase 1 | NCT01083407 | Jun 2005 → Jun 2006 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03004196 | Sep → Oct 2015 | smooth surface dental caries | Peoples University, Bhanpur, Bhopal | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06712433 | Sep 2026 → Sep 2028 expected | soft tissue sarcoma | Adam Olson | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05709015 | Jan → Feb 2023 | gingivitis | University of Ljubljana | Completed | No outcome recorded |
| Phase 2 | NCT05059145 | Apr 2022 → Dec 2024 | vulvovaginal candidiasis | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 2 | NCT05090657 | Feb → Aug 2022 | nosocomial infection | Ondine Biomedical Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03423147 | Oct 2018 → Feb 2021 | nosocomial infection | Angela Bianco | Terminated | No outcome recorded |
| Phase 2 | NCT03489629 | Apr 2018 → Sep 2025 | cystic fibrosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03681990 | Jun → Jul 2017 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 2 | NCT03326726 | Nov 2016 | — | Medline Industries | Completed | No outcome recorded |
| Phase 2 | NCT04830969 | Nov 2016 → Jan 2021 | periodontitis, type 2 diabetes mellitus | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT02589067 | Oct 2015 → Oct 2017 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02502682 | Jul 2015 → Jun 2016 | Clostridium difficile colitis | Jared Brooks | Completed | No outcome recorded |
| Phase 2 | NCT02447497 | Mar → Apr 2015 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 2 | NCT02605382 | Oct 2012 → Dec 2013 | mucositis | Federal University of Rio Grande do Norte | Completed | No outcome recorded |
| Phase 2 | NCT02639377 | Oct 2012 → Dec 2013 | gingivitis | Federal University of Rio Grande do Norte | Completed | No outcome recorded |
| Phase 2 | NCT02194023 | Sep 2011 → Jul 2013 | smooth surface dental caries | Universitat Internacional de Catalunya | Completed | No outcome recorded |
| Phase 2 | NCT01349192 | Apr 2011 → Jan 2015 | cystic fibrosis, methicillin-resistant staphylococcus aureus infectious disease | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT01079663 | Mar 2010 → Oct 2011 | periodontal disorder | Dexcel Pharma Technologies Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00123123 | Mar 2004 → Nov 2007 | pneumonia | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT00006075 | ? → Aug 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT01241318 | Feb 2011 → Sep 2013 | infectious disease with sepsis | Boston University | Completed | No outcome recorded |
| Phase 2/3 | NCT00549393 | Feb 2008 → Dec 2010 | nosocomial infection | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00516906 | Oct → Dec 2007 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT00272675 | Aug 2003 → Sep 2005 | nosocomial infection, respiratory tract infectious disorder | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT06126614 | May 2024 → Nov 2028 expected | periprosthetic joint infection | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT07142408 | Mar 2023 → Oct 2030 expected | — | The Cooper Health System | Recruiting | No outcome recorded |
| Phase 3 | NCT04218110 | Feb → Mar 2020 | — | Professional Disposables International, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04048356 | Jul 2019 → Feb 2021 | female reproductive system disorder, pelvic organ prolapse, urinary tract infection | University of New Mexico | Completed | No outcome recorded |
| Phase 3 | NCT03442023 | Feb → Nov 2019 | — | University of Guanajuato | Unknown | No outcome recorded |
| Phase 3 | NCT02490631 | Aug 2015 → Dec 2018 | — | Vanderbilt University | Completed | No outcome recorded |
| Phase 3 | NCT02526667 | Aug → Dec 2015 | — | Medline Industries | Completed | No outcome recorded |
| Phase 3 | NCT02291601 | Oct 2014 → Sep 2015 | — | Medline Industries | Completed | No outcome recorded |
| Phase 3 | NCT02224625 | Aug 2014 → Jun 2015 | — | Medline Industries | Completed | No outcome recorded |
| Phase 3 | NCT02222896 | Aug → Nov 2014 | — | Medline Industries | Completed | No outcome recorded |
| Phase 3 | NCT02080403 | Jul 2014 → Oct 2018 | periodontitis | Dexcel Pharma Technologies Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01613365 | May 2012 → May 2015 | respiratory tract infectious disorder | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01321125 | Apr → Dec 2011 | infectious disease | University of Guanajuato | Completed | No outcome recorded |
| Phase 3 | NCT01249846 | Dec 2010 → ? | periodontitis, chronic, adult | Dexcel Pharma Technologies Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00799812 | Nov 2007 → Apr 2008 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 3 | NCT00692484 | Oct 2007 → Feb 2008 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 3 | NCT00636480 | Oct 2007 → Mar 2008 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 3 | NCT00066950 | Mar 2003 → Jul 2005 | dental caries | University of California, San Francisco | Completed | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT06942026 | Apr → May 2025 overdue | mouth mucosa disorder | Aydin Adnan Menderes University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07203326 | Feb 2025 → Aug 2026 overdue | gingival recession | Ohio State University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06210594 | Apr 2024 → Nov 2025 | staphylococcus aureus infection | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 4 | NCT05920122 | Oct 2023 → Oct 2025 | — | Hyagriv Simhan | Completed | No outcome recorded |
| Phase 4 | NCT04941131 | May → Jul 2023 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT05303805 | May 2022 → Apr 2026 overdue | ulcer of lower limbs | Charles University, Czech Republic | Recruiting | No outcome recorded |
| Phase 4 | NCT06144983 | Feb → Sep 2022 | impacted teeth, multiple | University of Baghdad | Completed | No outcome recorded |
| Phase 4 | NCT04954313 | Sep 2021 → Feb 2025 | cardiovascular disorder, type 2 diabetes mellitus | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT03938467 | Mar 2021 → Jul 2023 | — | Orthopaedic Associates of Michigan, PC | Completed | No outcome recorded |
| Phase 4 | NCT04718922 | Jan → Jun 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04654182 | Nov → Dec 2020 | — | Molnlycke Health Care AB | Completed | No outcome recorded |
| Phase 4 | NCT04454619 | Jul 2020 | — | Centro Ortopedico y Quirurgico del Pie | Completed | No outcome recorded |
| Phase 4 | NCT04235985 | Jan → Apr 2020 | — | Molnlycke Health Care AB | Completed | No outcome recorded |
| Phase 4 | NCT03401749 | Nov 2018 → Dec 2020 | — | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 4 | NCT06733506 | Oct 2018 → May 2019 | substance-related disorder | Gabriel John Culbert | Completed | No outcome recorded |
| Phase 4 | NCT03385304 | Apr 2018 → Oct 2021 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT03574246 | Jan → Dec 2018 | pharyngitis | Ankara University | Completed | No outcome recorded |
| Phase 4 | NCT03372122 | Dec 2017 → Jan 2018 | — | Caroline Scott | Completed | No outcome recorded |
| Phase 4 | NCT03305159 | Aug 2017 → Apr 2018 | — | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT03209466 | May 2017 → Dec 2020 | — | University of Guanajuato | Unknown | No outcome recorded |
| Phase 4 | NCT03133312 | May → Dec 2017 | bacterial infectious disease | Metro Health, Michigan | Completed | No outcome recorded |
| Phase 4 | NCT03014778 | Jan 2017 → Dec 2018 | — | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 4 | NCT02319668 | Feb → Jun 2015 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02182115 | Jul 2014 → Aug 2016 | staphylococcus aureus infection | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT02154594 | Feb → Mar 2014 | gingivitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| Phase 4 | NCT02215473 | Aug → Dec 2013 | gingivitis, periodontitis | University of Taubate | Completed | No outcome recorded |
| Phase 4 | NCT01857804 | Jan 2013 → Nov 2014 | periodontal disorder | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT01919593 | Jan → Dec 2012 | bacterial infectious disease | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT01537783 | Sep 2011 → Sep 2013 | abscess | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02446158 | May 2010 → May 2011 | — | E-DA Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00610324 | May 2004 → Oct 2007 | aspiration pneumonia, bacterial pneumonia, nosocomial infection | King Edward Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07252258 | Jul 2025 → Feb 2026 overdue | periapical periodontitis | Aqsa Afzal | Active not recruiting | No outcome recorded |
| — | NCT06590675 | Feb → Mar 2025 | primary bacterial infectious disease | University of Pennsylvania | Terminated | No outcome recorded |
| — | NCT07364435 | Sep 2024 → Jan 2025 | Enterococcus infectious disease | Özkan Kasap | Completed | No outcome recorded |
| — | NCT06464770 | Aug 2024 → Dec 2026 expected | periprosthetic joint infection | University of Washington | Recruiting | No outcome recorded |
| — | NCT06305546 | Apr → Oct 2023 | gingivitis | Anam Sattar | Completed | No outcome recorded |
| — | NCT06531720 | Jan → Dec 2023 | ulcerative stomatitis | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT06691841 | Sep 2022 → May 2023 | — | Shanghai 10th People's Hospital | Completed | No outcome recorded |
| — | NCT05120739 | Nov 2021 → May 2023 | — | University Hospital, Grenoble | Completed | No outcome recorded |
| — | NCT04723446 | May → Oct 2021 | COVID-19 | Queen Mary University of London | Completed | No outcome recorded |
| — | NCT06284174 | Jan 2021 → Dec 2024 overdue | — | National Cheng-Kung University Hospital | Recruiting | No outcome recorded |
| — | NCT07365956 | Jan 2021 → Jan 2022 | — | Harran University | Completed | No outcome recorded |
| — | NCT06936475 | Jun → Sep 2020 | endometritis | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT04483063 | Mar 2020 → Dec 2021 | — | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| — | NCT04505202 | Apr 2019 → Mar 2020 | tracheobronchitis | Karabuk University | Completed | No outcome recorded |
| — | NCT04821193 | Nov 2017 → Jul 2020 | dental caries, prosthesis-related infectious disease, toxic dermatosis | Istanbul University - Cerrahpasa | Completed | No outcome recorded |
| — | NCT03119831 | Nov 2015 → Jul 2016 | periodontitis | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| — | NCT02386592 | Sep 2015 → Apr 2017 | neonatal sepsis | Boston University | Completed | No outcome recorded |
| — | NCT02513784 | Aug 2015 → Dec 2017 | Barrett esophagus, esophageal adenocarcinoma, peptic esophagitis | Columbia University | Completed | No outcome recorded |
| — | NCT02216227 | Apr 2014 → Feb 2021 | — | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT01893060 | Jul 2013 → May 2014 | — | University of Virginia | Unknown | No outcome recorded |
| — | NCT01563406 | Mar 2012 → Jun 2013 | bacterial infectious disease | Rush University Medical Center | Completed | No outcome recorded |
| — | NCT01472549 | Sep 2011 → Jun 2015 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01382446 | Jul 2010 → Apr 2012 | — | St. Joseph's Hospital and Medical Center, Phoenix | Completed | No outcome recorded |
| — | NCT01232231 | Jul 2010 → Apr 2012 | methicillin-resistant staphylococcus aureus infectious disease | Joseph Kim | Completed | No outcome recorded |
| — | NCT01090479 | Jan → Aug 2010 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT00966446 | Sep 2009 → Sep 2014 | methicillin-resistant staphylococcus aureus infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00475930 | May → Nov 2007 | staphylococcus aureus infection | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| — | NCT00002431 | — | HIV infectious disease, oral candidiasis | Procter and Gamble | Completed | No outcome recorded |
Also used as a comparator or background therapy in 59 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03410602 Comparator | Apr 2016 → Aug 2017 | periodontitis | Meenakshi Ammal Dental College and Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03115892 Comparator | Apr → Sep 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06690814 Comparator | Oct → Nov 2024 | skin infection, ulcer disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 2 | NCT04748783 Comparator | Mar → Apr 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT03030989 Comparator | Jan 2017 → Jan 2019 | disease related to hematopoietic stem cell transplant | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT03140254 Comparator | Sep 2016 → Mar 2017 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 2 | NCT02598778 Comparator | Nov 2015 → Apr 2016 | dental caries | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01594827 Background | Oct 2012 → Dec 2017 | cystic fibrosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01014143 Comparator | Aug → Sep 2007 | smooth surface dental caries | Colgate Palmolive | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02943759 Comparator | Dec 2016 → Feb 2018 | suppurative periapical periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05110001 Background | Aug 2022 → Dec 2024 | Acanthamoeba keratitis, fungal keratitis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT04756804 Comparator | Jun 2021 → Sep 2022 | — | Zurex Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02848482 Background | May 2017 → May 2019 | periodontal disorder | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Completed | No outcome recorded |
| Phase 3 | NCT03061916 Comparator | Mar → May 2017 | dental caries | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT01495117 Comparator | Oct 2011 → Oct 2014 | — | Seung Duk Lee | Completed | No outcome recorded |
| Phase 3 | NCT00859235 Comparator | May → Nov 2009 | — | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01024738 Comparator | Mar → Apr 2008 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT00759187 Comparator | Jan → Apr 2008 | gingival disorder | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT00765167 Comparator | Nov → Dec 2007 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 420 trials | ||||||
| Phase 4 | NCT05586776 Comparator | Jan 2023 → Jan 2027 expected | — | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 4 | NCT07489924 Comparator | Jan 2023 → Jul 2025 overdue | periodontitis, type 2 diabetes mellitus | University of Colima | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05408923 Comparator | Jul 2022 → Jul 2025 | spondylosis | University of Missouri-Columbia | Withdrawn | No outcome recorded |
| Phase 4 | NCT05401292 Comparator | Feb 2022 → Dec 2026 expected | — | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT04942496 Comparator | Jun 2021 | irritant dermatitis | Molnlycke Health Care AB | Unknown | No outcome recorded |
| Phase 4 | NCT04683146 Comparator | Mar 2021 | — | Centro Ortopedico y Quirurgico del Pie | Unknown | No outcome recorded |
| Phase 4 | NCT04603794 Comparator | Oct → Nov 2020 | COVID-19 | Ohio State University | Unknown | No outcome recorded |
| Phase 4 | NCT03859908 Comparator | Apr 2019 → Jan 2021 | — | Universidad de El Salvador | Terminated | No outcome recorded |
| Phase 4 | NCT04021524 Comparator | Sep 2018 → May 2019 | acne | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03685604 Comparator | Sep 2018 → Jun 2020 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT03118232 Comparator | Apr 2017 → Oct 2023 | infectious disease | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT02029872 Comparator | Jan 2014 → Mar 2017 | methicillin-resistant staphylococcus aureus infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01962493 Background | Sep → Nov 2013 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01717690 Comparator | Aug 2013 → Sep 2014 | — | Baycrest | Completed | No outcome recorded |
| Phase 4 | NCT01751178 Comparator | Oct 2012 → Mar 2013 | gingivitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01782573 Comparator | Oct 2011 → Sep 2012 | liver and intrahepatic bile duct neoplasm | Changhua Christian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02433899 Background | Oct 2010 → Apr 2012 | gingival recession | Fluminense Federal University | Completed | No outcome recorded |
| Phase 4 | NCT00739583 Comparator | Aug 2008 → Aug 2009 | osteoarthritis, hip | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01030666 Background | Apr 2007 → Jan 2011 | periodontitis | Peter Eickholz | Terminated | No outcome recorded |
| Phase 4 | NCT02433912 Background | Jun 2002 → Dec 2011 | gingival recession | Fluminense Federal University | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07529444 Comparator | Mar 2026 → Mar 2027 expected | periodontal disorder | University of Zagreb | Recruiting | No outcome recorded |
| — | NCT06731881 Background | Jun 2025 → Jun 2026 overdue | nasal disorder | Guy's and St Thomas' NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT07180498 Comparator | Apr → Oct 2025 overdue | periodontal disorder | Harran University | Recruiting | No outcome recorded |
| — | NCT06521112 Background | May → Jul 2023 | mucositis | TC Erciyes University | Completed | No outcome recorded |
| — | NCT05816512 Comparator | Apr → Sep 2023 | dental caries, gingivitis, periodontitis | Ahmed Yousif Mahdi | Unknown | No outcome recorded |
| — | NCT07309679 Comparator | Mar → Jun 2023 | gingivitis | Mansoura University | Completed | No outcome recorded |
| — | NCT07466992 Comparator | Dec 2021 → Jul 2022 | impacted teeth, multiple | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT07610603 Comparator | Jan → Mar 2021 | smooth surface dental caries | Riyadh Elm University | Completed | No outcome recorded |
| — | NCT07689695 Comparator | Jun 2020 → Jul 2021 | — | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT03656588 Comparator | Apr 2018 → Jan 2019 | bacterial infectious disease | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT03588351 Comparator | Jan → Aug 2018 | dental pulp necrosis | Ain Shams University | Unknown | No outcome recorded |
| — | NCT02385708 Comparator | Aug 2015 → Jun 2018 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01640925 Comparator | Jul 2012 → May 2013 | nosocomial infection, urinary tract infection | Joshua Swan | Completed | No outcome recorded |
| — | NCT02709824 Comparator | Dec 2011 → Feb 2012 | — | University of Milan | Completed | No outcome recorded |
| — | NCT01233050 Comparator | Dec 2010 → Feb 2015 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01105767 Comparator | May 2010 → Jan 2012 | methicillin-resistant staphylococcus aureus infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| — | NCT00779246 Comparator | Jun 2008 → Jul 2009 | staphylococcal infection | Christiana Care Health Services | Completed | No outcome recorded |
| — | NCT01216761 Comparator | May 2008 → Sep 2009 | bacterial infectious disease | University of Michigan | Completed | No outcome recorded |
| — | NCT00908817 Comparator | May 2008 → Apr 2009 | — | Soonchunhyang University Hospital | Completed | No outcome recorded |
| — | NCT00867035 Comparator | Mar 2008 → Mar 2009 | — | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 176 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorhexidine Gluconate | “Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface...” NCT01321125 ↗143“Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS...” NCT01232231 ↗ “PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4,...” NCT01079663 ↗ “The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of...” NCT01249846 ↗ “Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic...” NCT01717690 ↗ “3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.” NCT01563406 ↗ “The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).” NCT04954313 ↗ “Patients were randomly assigned to use 2% chlorhexidine gluconate-impregnated cloths (treatment group) or to shower with soap and water before surgery (control group).” PMID 21612945 ↗ May 2011 “A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.” NCT06731881 ↗ “Participants were randomly assigned to receive oral care with ozonated water, hypochlorous acid, or 0.12% chlorhexidine gluconate.” PMID 41853915 ↗ Mar 2026 “Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation” NCT01472549 ↗ “Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.” NCT04048356 ↗ “Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812 ↗ “intranasal mupirocin ointment twice daily for 7 days and chlorhexidine gluconate on the first and last day” PMID 27465112 ↗ Jul 2016 “Chloraprep® (chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583 ↗ “Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin” NCT03681990 ↗ “0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent” NCT03410602 ↗ “The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains debated.” PMID 38884982 ↗ Aug 2024 “Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation.” NCT03938467 ↗ “Chlorhexidine gluconate (CHG) impregnated cloths in this indication.” PMID 41291848 ↗ Nov 2025 “Chlorhexidine gluconate liquid soap for bathing daily.” NCT02182115 ↗ “Chlorhexidine gluconate 2% / Isopropyl alcohol 70%” NCT02447497 ↗ “2% Chlorhexidine Gluconate” NCT02385708 ↗ “Chlorhexidine Gluconate” NCT02224625 ↗ “Chlorhexidine Gluconate” NCT03326726 ↗ |
| Known as | Antigerm Solution | “application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab” NCT02446158 ↗ |
| Known as | CHG | “The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during...” NCT05059145 ↗21“The purpose of this study is to determine whether daily bathing with 2% chlorhexidine gluconate-impregnated antiseptic cleanser (CHG) significantly reduces incidence of...” NCT01717690 ↗ “OBJECTIVE: To determine whether patients bathed daily with chlorhexidine gluconate (CHG) have a lower incidence of primary bloodstream infections (BSIs) compared with patients...” PMID 17954801 ↗ Oct 2007 “We hypothesized that oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate (CHG) would be an effective method to reduce these complications as reported...” PMID 29671041 ↗ Apr 2018 “This study will evaluate the amount of chlorhexidine gluconate (CHG) present on treated skin of human volunteers following different application times with a test material...” NCT04235985 ↗ “personal hygiene measures, including chlorhexidine (CHG) body wash, did not prevent overall and methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue...” PMID 25421482 ↗ Nov 2014 “Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children.” PMID 23363666 ↗ Jan 2013 “Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583 ↗ “2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG” NCT01216761 ↗ “Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812 ↗ “Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.” NCT02447497 ↗ “Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes.” NCT06733506 ↗ “2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering.” NCT03118232 ↗ “Chlorhexidine gluconate (CHG) impregnated cloths in this indication.” PMID 41291848 ↗ Nov 2025 “0.05% chlorhexidine gluconate (CHG) solution for soaking the wound” NCT06284174 ↗ “2% chlorhexidine gluconate (CHG) impregnated cloths” NCT00475930 ↗ “4% chlorhexidine gluconate (CHG) in purified water” NCT03385304 ↗ “0.2% chlorhexidine gluconate (CHG) solution” NCT00610324 ↗ “chlorhexidine gluconate [CHG] bathing” PMID 30037355 ↗ Jul 2018 “Chlorhexidine Gluconate in IMS, CHG” NCT02216227 ↗ “Chlorhexidine gluconate (CHG)” NCT02386592 ↗ “Chlorhexidine Gluconate (CHG)” NCT06590675 ↗ |
| Known as | ChloraPrep | “The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical...” NCT01321125 ↗ |
| Known as | chlorhexidine | “Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and...” NCT01105767 ↗ |
| Known as | Chlorhexidine Digluconate | “The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20%...” NCT05303805 ↗16“Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.” NCT04454619 ↗ “0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis.” NCT07489924 ↗ “new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023 ↗ “0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.” NCT02848482 ↗ |
| Known as | Chlorhexidine Gluconate in IMS | “Chlorhexidine Gluconate in IMS, CHG” NCT02216227 ↗ |
| Known as | Chlorhexidine Gluconate in IMS, CHG | “Chlorhexidine Gluconate in IMS, CHG” NCT02216227 ↗ |
| Known as | Chlorhexidine Gluconate Mouthwash | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03787082 ↗ |
| Known as | Chlorhexidine mouthwash | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03115892 ↗ |
| Known as | chlorohexidine | “chlorohexidine mouthwash take two times per day for one week” NCT03115892 ↗ |
| Known as | chorhexidine digluconate | “The aim of the study was comparing the effectiveness of oral mucosa healing properties of different preparations: CHX=0,2% chorhexidine digluconate, CHS=8,7% choline...” NCT06531720 ↗ |
| Known as | CHX | “The aim of the study was comparing the effectiveness of oral mucosa healing properties of different preparations: CHX=0,2% chorhexidine digluconate, CHS=8,7% choline...” NCT06531720 ↗3“new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023 ↗ “rinsing with: Group 1-0.2% Chlorhexidine digluconate (CHX); Group 2-1.5% Hydrogen peroxide (H2O2);” PMID 37542087 ↗ Aug 2023 “such as those containing chlorhexidine digluconate (CHX)” PMID 27557865 ↗ Aug 2016 |
| Known as | Clorhexidine digluconate | “Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)” NCT02194023 ↗ |
| Known as | Dr. Reddy's Clohex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004196 ↗ |
| Known as | DynaHex | “DynaHex (2% CHG)” NCT02224625 ↗ |
| Known as | HEXIDINE | “0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent” NCT03410602 ↗ |
| Known as | Hibiclens | “Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and...” NCT01105767 ↗ |
| Known as | Kloroben | “Commercially available 0.2% chlorhexidine gluconate mouthrinse (Kloroben®, Drogsan, Ankara, Türkiye).” NCT07689695 ↗ |
| Known as | MicroDerm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203326 ↗ |
| Known as | Perio-Aid Treatment | “Perio-Aid Treatment” NCT02194023 ↗ |
| Known as | PerioChip | “The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of...” NCT01249846 ↗1“Chlorhexidine Gluconate chip (Periochip®)” NCT01079663 ↗ |
| Known as | Periogard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04748783 ↗ |
| Known as | ReadyPrep CHG | “Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth)” NCT03331263 ↗ |
| Known as | Softasept | “CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG)” NCT03685604 ↗ |
| Modality | Other / unclassified | “rapid onset, broad spectrum, topical antiseptic” NCT02326467 ↗ |
| Route | Oral | “an oral rinse containing chlorhexidine gluconate” NCT00002431 ↗ |